Clinical Trial Update: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating rituximab, lenalidomide, and ibrutinib in patients with previously untreated stage II-IV follicu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING